Medacta was granted approval under the CE Mark for its Long Humeral Diaphysis and Stemless Humeral Metaphysis implants for its shoulder joint replacement system, pictured above.
The Long Humeral Diaphysis, which recently obtained FDA 510(k) clearance, can be used in complex cases particularly when there is a need for extended distal fixation.
The Stemless Humeral Metaphysis is intended for use in anatomic configuration and enables a minimally invasive approach at the humeral level, preserving the humeral canal. The implant features Medacta’s 3D Metal surface designed to improve the metal/bone bond.
Francesco Siccardi, CEO, said, “With the new Stemless Humeral Metaphysis, Medacta is now able to offer a minimally invasive solution for shoulder arthroplasty and continue our commitment to improve the care and well-being of orthopaedic patients around the world.”
Medacta was granted approval under the CE Mark for its Long Humeral Diaphysis and Stemless Humeral Metaphysis implants for its shoulder joint replacement system, pictured above.
The Long Humeral Diaphysis, which recently obtained FDA 510(k) clearance, can be used in complex cases particularly when there is a need for extended distal...
Medacta was granted approval under the CE Mark for its Long Humeral Diaphysis and Stemless Humeral Metaphysis implants for its shoulder joint replacement system, pictured above.
The Long Humeral Diaphysis, which recently obtained FDA 510(k) clearance, can be used in complex cases particularly when there is a need for extended distal fixation.
The Stemless Humeral Metaphysis is intended for use in anatomic configuration and enables a minimally invasive approach at the humeral level, preserving the humeral canal. The implant features Medacta’s 3D Metal surface designed to improve the metal/bone bond.
Francesco Siccardi, CEO, said, “With the new Stemless Humeral Metaphysis, Medacta is now able to offer a minimally invasive solution for shoulder arthroplasty and continue our commitment to improve the care and well-being of orthopaedic patients around the world.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
